Intuitive Surgical stock gains on strong Q2 2026 margins and recurring revenue
Published on 09/04/2026 at 19:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical stock (ISIN US46120E6023) is drawing renewed investor attention on September 4, 2026, after the company reported a robust Q2 2026 with double-digit revenue growth and rising margins, while the shares trade significantly below their 52-week high according to MarketBeat data as of early September 2026.
Q2 2026 figures show double-digit growth
According to a Q2 2026 comparison of Intuitive Surgical and Stryker compiled by 247WallSt, Intuitive Surgical grew its revenue by 18.5 percent in Q2 2026, outpacing Stryker, which reported 9.4 percent growth in the same period.
The same 247WallSt overview notes that Intuitive Surgical’s recurring revenue reached 85 percent of total revenue in Q2 2026, underpinned by procedure volumes and the installed base of da Vinci systems, while instruments and accessories generated USD 1.73 billion, up 18 percent year over year in that quarter.
Margins and earnings beat support valuation
In Q2 2026, Intuitive Surgical’s non-GAAP gross margin expanded to 70.0 percent, according to the 247WallSt analysis, giving the company a higher margin profile than Stryker’s 66 percent gross margin over the same period and reinforcing the profitability of its robotic surgery platform.
MarketBeat data on institutional and analyst coverage indicate that Intuitive Surgical reported Q2 2026 earnings per share of USD 2.80, ahead of consensus estimates of USD 2.48, while revenue for the quarter came in at USD 2.89 billion, representing an 18.4 percent year-over-year increase.
For investors, the combination of an earnings beat of USD 0.32 per share versus consensus and nearly 18.5 percent revenue growth in Q2 2026 underscores that Intuitive Surgical is still delivering strong operational momentum despite a rich valuation multiple.
Installed base and da Vinci placements
The Q2 2026 comparison from 247WallSt highlights that Intuitive Surgical placed 468 da Vinci surgical systems in the quarter, including 246 units of the latest generation da Vinci 5 system, reflecting continued adoption of robotic-assisted surgery by hospitals and surgical centers.
This placement figure, coupled with high recurring revenue, suggests that Intuitive Surgical’s model is increasingly driven by procedures and consumables rather than one-off capital sales, a dynamic that can smooth revenue over time.
Analyst consensus and valuation context
According to MarketBeat data on Intuitive Surgical and institutional investors published on September 4, 2026, shares of Intuitive Surgical opened at USD 369.83, compared with a 52-week high of USD 603.88 and a 1-year low of USD 328.57.
The same MarketBeat overview cites a market capitalization of USD 130.65 billion as of early September 2026, with a price-to-earnings ratio of 42.36 and a PEG ratio of 2.81, metrics that reflect a premium valuation but also strong expected growth in earnings.
Analyst sentiment remains clearly positive, with MarketBeat reporting an average rating of Moderate Buy and a consensus price target of USD 508.68 for Intuitive Surgical, indicating that analysts see upside of more than USD 130 per share from the USD 369.83 opening level referenced in early September 2026.
Institutional investors increase exposure
Institutional investors continue to play a major role in Intuitive Surgical’s shareholder base. MarketBeat notes that institutional investors collectively own around 83.64 percent of the company’s stock, a high level that can support liquidity and long-term capital stability.
One example is NEOS Investment Management LLC, which increased its position in Intuitive Surgical by 10.2 percent in the second quarter, adding 25,047 shares to reach 269,580 shares valued at approximately USD 107.2 million, according to the MarketBeat filing summary dated September 4, 2026.
Another MarketBeat alert points out that CIBC Capital Markets Europe acquired 48,252 Intuitive Surgical shares worth about USD 19.19 million, making the position its ninth-largest holding and representing 2.6 percent of its portfolio, underlining rising institutional confidence in the company’s long-term prospects.
Product focus: da Vinci surgical system
At the heart of Intuitive Surgical’s business model is the da Vinci robotic surgical system, which enables minimally invasive procedures across multiple specialties, including urology, gynecology and general surgery, and generates recurring revenue through instruments and accessories used in each procedure.
The Q2 2026 data indicating 468 da Vinci placements, including 246 da Vinci 5 units, suggest that hospitals continue to upgrade and expand their fleets to access the latest features in imaging, ergonomics and software that can improve surgeon precision and patient outcomes.
Stock level and investor takeaway
Based on MarketBeat price performance data as of early September 2026, Intuitive Surgical stock opened at USD 369.83, a level that sits well above the 1-year low of USD 328.57 but substantially below the 52-week high of USD 603.88, giving investors a clear sense of the current trading band.
Intuitive Surgical stock at a glance
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Trading venue: NASDAQ
- Price (as of September 4, 2026): 369.83 USD
- Market capitalization: 130.65 billion USD (as of September 4, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
